Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Advancing High-Content Analysis for Cancer Applications

Published: Tuesday, April 08, 2014
Last Updated: Tuesday, April 08, 2014
Bookmark and Share
A new high-content screening software platform enables cancer researchers to uncover more about basic and advanced cellular function to accelerate cell-based research.

The Thermo Scientific HCS Studio 2.0 is a high-content quantitative imaging and analysis software platform for a range of cancer research applications, including angiogenesis and migration/invasion, as well as the development of three-dimensional models of cancer stem cells and spheroid tumors. 

The new Thermo Scientific HCS Studio 2.0, coupled with Thermo Scientific high content analysis platforms, are increasingly being used in cancer biology as they are well suited for large-scale, high-throughput biology, including complex morphological analyses of cells, cell structure, and aggregations of cells in colonies, yet simple enough to be applied to everyday assays such as viability and proliferation. 

The Thermo Scientific HCS Studio 2.0 and the ArrayScan XTI High Content Analysis (HCA) platform will be demonstrated during the American Association for Cancer Research (AACR) 105th Annual Meeting (Booth #1107), April 5 - 9, 2014 at the San Diego Convention Center. 

“The challenges posed by complex cancer applications and cell models demand new types of quantitative analysis techniques, and our new software continues to enable researchers with innovative assay techniques and functionality, allowing further discovery using complex cell models,” said Scott Keefer, manager of product marketing, cellular imaging and analysis, Thermo Fisher Scientific. “With our new HCS Studio 2.0 software, coupled with the Thermo Scientific ArrayScan XTI HCA Infinity Configuration enabled for 3D confocal imaging, our customers can address more assay and cell types than ever before while managing the complexities of high-content technology with user-guided, task-oriented software.” 

Featuring a validated image processing tool and a powerful yet simple user interface, the HCS Studio 2.0 provides researchers with innovative assay techniques and functionality, allowing further discovery using complex cell models. Additional features include: 

• Directed Assay or Full Development Environment: Pick from validated assays or a customized design with a full suite of image processing tools 

• Simple interactive tools for assay optimization: Best-in-class user tools to improve the performance and accuracy of image analysis on cells 

• Seamless Integration: Works with software from Thermo Scientific High-Content Imaging platforms for a scalable quantitative cell analysis platform


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Thermo Fisher Scientific to Acquire Life Technologies Corporation
The definitive agreement will see Thermo Fisher will acquire Life Technologies for $76.00 in cash per fully diluted common share or approximately $13.6 billion.
Monday, April 15, 2013
Thermo Scientific Named Company of the Year for Integrated Biobanking Solutions by Frost & Sullivan
Unlike competitors, the Company offers comprehensive biobanking products, services and solutions aimed at improving quality and simplifying the management of biobanks.
Wednesday, June 13, 2012
Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!